Brett CPJ, Cano-Carmona AD, Guevara-Lizarazo GA, Meza-Fandiño DF, Ortega-Sierra MG

Language: Spanish
References: 7
Page: 5-6
PDF size: 125.73 Kb.

Text Extraction

No abstract.

REFERENCES

1. Pan American Health Organization. The burden of Neurologicalconditions in the Region of the Americas, 2000-2019. PanAmerican Health Organization; 2021. https://www.paho.org/en/enlace/burden-neurological-conditions

2. Lozada-Martínez I, Maiguel-Lapeira J, Torres-Llinás D, Moscote-Salazar L, Rahman MM, Pacheco-Hernández A. Letter: Needand impact of the development of robotic neurosurgery inLatin America. Neurosurgery. 2021; 88(6):E580-E581. doi:10.1093/neuros/nyab088

3. Vaishnav AG. Is tenecteplase a viable alternative to alteplase inthe treatment of acute ischemic stroke? Ann Indian Acad Neurol.2022; 25(5):794-5. doi: 10.4103/aian.aian_668_22

4. Wang Y, Li S, Pan Y, Li H, Parsons MW, Campbell BCV, et al.Tenecteplase versus alteplase in acute ischaemic cerebrovascularevents (TRACE-2): a phase 3, multicentre, open-label,randomised controlled, non-inferiority trial. Lancet. 2023;401(10377):645-54. doi: 10.1016/S0140-6736(22)02600-9

5. Kvistad CE, Næss H, Helleberg BH, Idicula T, HagbergG, Nordby LM, et al. Tenecteplase versus alteplase for themanagement of acute ischaemic stroke in Norway (NOR-TEST 2,part A): a phase 3, randomised, open-label, blinded endpoint,non-inferiority trial. Lancet Neurol. 2022; 21(6):511-9. doi:10.1016/S1474-4422(22)00124-7

6. Roaldsen MB, Eltoft A, Wilsgaard T, Christensen H, EngelterST, Indredavik B, et al. Safety and efficacy of tenecteplase inpatients with wake-up stroke assessed by non-contrast CT(TWIST): a multicentre, open-label, randomised controlledtrial. Lancet Neurol. 2023; 22(2):117-26. doi: 10.1016/S1474-4422(22)00484-7

7. Kobeissi H, Ghozy S, Turfe B, Bilgin C, Kadirvel R, Kallmes DF,et al. Tenecteplase vs. alteplase for treatment of acute ischemicstroke: A systematic review and meta-analysis of randomizedtrials. Front Neurol. 2023; 14:1102463. doi: 10.3389/fneur.2023.1102463